HTD 1801

Drug Profile

HTD 1801

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HighTide Biopharma
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Primary sclerosing cholangitis

Most Recent Events

  • 07 Nov 2017 HighTide Biopharma plans a phase II study for Primary sclerosing cholangitis (Adults, Second-line or greater therapy) in Australia in December 2017 (NCT03333928)
  • 03 Oct 2017 HighTide Biopharma completes a phase I trial in Primary sclerosing cholangitis in Australia (PO) (NCT03099603)
  • 24 Mar 2017 Phase-I clinical trials in Primary sclerosing cholangitis in Australia (PO) (NCT03099603)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top